Table 3.
Treatment approaches
| Treatment approaches | SBP | EMP | Patients, n (%) |
|---|---|---|---|
| RT alone | 16 | 9 | 25 (37.9%) |
| RT + CT | 4 | 0 | 4 (6.1%) |
| Surgery alone | 12 | 2 | 14 (2.2%) |
| Surgery + RT | 9 | 10 | 19 (28.8%) |
| Surgery + CT | 3 | 0 | 3 (4.5%) |
| CT regimens | |||
| VAD | 4 | 0 | 4 (6.1%) |
| MP | 2 | 0 | 2 (3.1%) |
| VBMCP | 1 | 0 | 1 (1.5%) |
| Radiation dose | |||
| ≤40 Gy | 8 | 3 | 11 (16.7%) |
| >40 to ≤50 Gy | 13 | 12 | 25 (37.9%) |
| >50 Gy | 8 | 4 | 12 (18.2%) |
Notes: The chemotherapy regimens were: VAD, consisting of vincristine + epirubicin + dexamethasone; MP, consisting of melphalan + prednisone; and VBMCP, consisting of carmustine + cyclophosphamide + vincristine + melphalan + prednisone.
Abbreviations: CT, chemotherapy; EMP, extramedullary plasmacytoma; RT, radiotherapy; SBP, solitary bone plasmacytoma.